BT-301 / Oscotec - LARVOL DELTA

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC (clinicaltrials.gov) - P1/2 | N=66 | Recruiting | Sponsor: Anbogen Therapeutics, Inc.

Mismatch repair • MSI-H • New P1/2 trial • pMMR • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor

Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor, in patients with advanced solid tumors. (ASCO 2023) - P1 | "Preclinical studies showed that ABT-301 had a stronger apoptotic activity and inhibited HDAC activity more potently than vorinostat. ABT-301 was well-tolerated at a daily dose of up to 150 mg and demonstrated objective responses and long-term SD across multiple tumor types at MTD. The safety profile of ABT-301 was superior to known HDAC inhibitors with only predictable HDAC inhibitor-related toxicities observed but no cardiac toxicity, neutropenia, nor lymphopenia elicited. Non-clinical and clinical results suggested the potential clinical development of ABT-301 in combination with myelosuppressive agents and immunotherapies."

Clinical • Metastases • P1 data • Anemia • Anorexia • Colorectal Cancer • Diabetes • Endometrial Cancer • Fatigue • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Hepatocellular Cancer • Immune Modulation • Lymphoma • Mucositis • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pain • Renal Cell Carcinoma • Salivary Gland Cancer • Sarcoma • Solid Tumor • Thrombocytopenia • Thymus Cancer • HDAC11